PE-22-28 Protocol
Dosing & Research
Last Updated: September 4, 2026
Rapid-acting antidepressant research, TREK-1 inhibition, Neurogenesis studies, Mood and cognition models
Half-Life
Not Well Characterized
Administration
Subcutaneous
Frequency
Once Daily
How It Works
- Rapid-acting antidepressant research
- TREK-1 inhibition
- Neurogenesis studies
- Mood and cognition models
Dosing Structure
Dose
50–200 mcg daily
Frequency
Once Daily
Notes
Inject: Abdominal fat, thigh (rotate). Morning administration common. Break: 4 weeks on, 2-4 weeks off.
Example Protocols
Dose: 50–200 mcg daily
Frequency: Once Daily
Duration: 4-8 weeks
Off Period: Not listed
Find Research Grade PE-22-28
Recommended vendors for sourcing research-grade material. PeptaBase does not sell peptides directly.
Vendor One Research Labs
COA VerifiedThird-party COA-verified research peptides with published batch testing.
Source Coming SoonVendor Two Sciences
Purity TestedUS-based research compound supplier with independent purity testing.
Source Coming SoonVendor Three Peptide Co.
Bulk research peptide sourcing with batch-level documentation.
Source Coming SoonProtocol Notes
•
Inject: Abdominal fat, thigh (rotate).
•
Morning administration common.
•
Break: 4 weeks on, 2-4 weeks off.
Research & Studies
Loading citations…
Research Feedback
0 approved
For research discussion only. Community feedback is moderated and shown here as aggregated insights after approval.
Be the first to submit research feedback for this peptide.
Approved submissions will appear here as aggregated insights.